ACRO Biomedical Co., Ltd. (TPEX:6748)

ACRO Biomedical Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	449.48	770.67	191.75	544.16	281.85	32.26
Short-Term Investments	467.2	207.2	307.2	35.07	35.01	30.71
Cash & Short-Term Investments	916.68	977.87	498.95	579.23	316.85	62.97
Cash Growth	102.24%	95.99%	-13.86%	82.81%	403.18%	-46.08%
Accounts Receivable	13.32	3.13	7.87	4.83	10.3	6.23
Other Receivables	1.05	0.96	2.15	3.39	0.17	0.08
Receivables	14.38	4.09	10.02	8.23	10.47	6.31
Inventory	16.13	12.7	10.7	9.51	12.51	14.63
Prepaid Expenses	11.57	11.24	9.71	10.85	11.01	18.27
Total Current Assets	958.76	1,006	529.38	607.81	350.84	102.17
Property, Plant & Equipment	88.45	53.7	56.23	45.81	21.89	26.39
Long-Term Investments	49.47	47.46	46.06	47.39	13.74	13.24
Other Intangible Assets	6.27	6.91	6.33	8.47	8.01	7.97
Other Long-Term Assets	7.68	18.66	17.32	7.25	4.05	1.51
Total Assets	1,111	1,133	655.33	716.74	398.53	151.29

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	0.17	1.03	0.75	0.95	1.21	0.11
Accrued Expenses	9.95	15.16	9.85	8.09	7.72	7.53
Current Portion of Leases	4.09	2.16	5.26	5.25	3.67	3.39
Current Unearned Revenue	1.07	0.88	2.5	0.19	0.08	0.31
Other Current Liabilities	0.12	0.45	0.1	0.33	-	-
Total Current Liabilities	15.39	19.68	18.46	14.81	12.68	11.34
Long-Term Leases	29.55	8.43	10.59	15.85	7.25	9.93
Total Liabilities	44.94	28.11	29.05	30.66	19.92	21.27

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	712.18	712.18	612.18	612.18	512.18	354.33
Additional Paid-In Capital	713.96	713.52	251.39	250	160.3	9.56
Retained Earnings	-359.59	-319.37	-236.71	-174.62	-293.5	-232.62
Comprehensive Income & Other	-0.87	-1.82	-0.59	-1.48	-0.37	-1.25
Shareholders' Equity	1,066	1,105	626.28	686.08	378.61	130.02
Total Liabilities & Equity	1,111	1,133	655.33	716.74	398.53	151.29

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	33.63	10.59	15.85	21.1	10.92	13.32
Net Cash (Debt)	883.05	967.28	483.1	558.13	305.93	49.65
Net Cash Growth	100.66%	100.22%	-13.44%	82.43%	516.20%	-51.44%
Net Cash Per Share	13.33	15.79	7.89	10.59	6.46	1.40
Filing Date Shares Outstanding	71.22	71.22	61.22	61.22	51.22	35.43
Total Common Shares Outstanding	71.22	71.22	61.22	61.22	51.22	35.43
Working Capital	943.36	986.22	510.92	593	338.16	90.83
Book Value Per Share	14.96	15.51	10.23	11.21	7.39	3.67
Tangible Book Value	1,059	1,098	619.94	677.61	370.6	122.05
Tangible Book Value Per Share	14.88	15.41	10.13	11.07	7.24	3.44
Machinery	74.56	71.33	59.3	45.42	43.94	41.93
Construction In Progress	13.85	0.63	0.63	16.51	-	-
Leasehold Improvements	59.44	59.44	59.04	36.36	36.35	36.35

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 3, 2026

Data Sources Report a data error